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Pharmacology and clinical potential  
of vortioxetine in the treatment  
of major depressive disorder
Abstract: Vortioxetine is a new multimodal action antidepressant with two types of action: 
serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic recep-
tors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and 
an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic 
receptors increases the extracellular concentration of serotonin, dopamine, and noradrena-
line. Twelve  clinical trials have been carried out, nine of which had positive results versus 
placebo. When active comparators were included in the study design, no significant differ-
ences were found except in one study in which the efficacy of vortioxetine was superior to 
the comparator (agomelatine) in depression resistant to selective serotonin reuptake inhibitors 
(SSRI)/serotonin–norepinephrine reuptake inhibitors (SNRI) treatment. Tolerability studies 
indicate that the drug does not cause any important problems on blood tests, vital signs, or on 
electrocardiography. The lack of weight gain and induction of metabolic syndrome and the 
lack of significant changes in the QTc are especially important. The incidence rate of sexual 
dysfunction is low and similar to placebo in various trials. Similarly, cognitive function remains 
intact with vortioxetine.
Keywords: depression, clinical trial, efficacy
Introduction
Major depressive disorder (MDD) is a disease that most commonly emerges in the 
third decade of life, with a high relapse rate and risk of chronicity. MDD is undoubt-
edly the maximum expression of human suffering and is the leading cause of death 
by suicide.
MDD is a common disease, with lifetime prevalence of around 13% and an inci-
dence rate of 4%.1 Females are twice as likely to suffer from major depression as males, 
and it is the main cause of suicide in both sexes. Approximately 15% of patients with 
depression die as a consequence of the illness2 and MDD accounts for at least 90% 
of all suicides. Suicide is currently the main cause of external death in all age groups 
in most European countries. 
Sufficient evidence is available to support the idea that depression is a neuroprogres-
sive disease, that is, the persistence of the clinical signs and symptoms implies structural 
changes in the neurons and neural tracts.3,4 Due to this neuroprogression, it is even more 
important to achieve the therapeutic objectives as quickly and effectively as possible.
The total cost of depression in Europe has been estimated at €118 billion, with the 
majority of this amount (61%) due to indirect costs related to workplace productivity 
losses.5
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According to the World Health Organization (WHO), 
depression is the second leading cause of disability – 
expressed as disability-adjusted life years (DALYs), that 
is, years of healthy life lost – in patients aged 15–44 years. 
For 2020, the WHO estimates that depression will become 
the second leading cause of disability (DALYs) for all age 
groups. By 2030, depression is expected to become the lead-
ing cause of disability in industrialized countries.6
Despite the large number of antidepressants on the 
market, the treatment of depression still has numerous 
unmet needs, most of which are related to the efficacy and 
tolerability of the currently available drugs. Specifically, 
most antidepressants negatively affect sexual and cognitive 
function and can induce weight gain, and these effects often 
lead to therapeutic discontinuation. These treatment interrup-
tions, in turn, increase the number of episodes and the risk of 
chronicity. Consequently, all of these factors taken together, 
increase the costs of depression at all levels (ie, personal, 
family, and economic). 
The arrival of a new antidepressant on the market – 
 vortioxetine – that could partially mitigate these negative 
aspects will undoubtedly generate strong interest.
Mechanism of action of vortioxetine
Vortioxetine shows high affinity for the serotonin transporter 
(SERT) and several serotonin receptors. Thus, in vitro 
assay revealed that vortioxetine is a 5-hydroxytryptamine 
(5-HT)
3
, 5-HT
7
, and 5-HT
1D
 receptor antagonist, a 5-HT
1B
 
receptor partial agonist, a 5-HT
1A
 receptor agonist, and 
SERT inhibitor.7–9 Binding affinities and functional activi-
ties of vortioxetine are similar in rat and human brain, with 
the exception of 5-HT
7
 and 5-HT
1A
 receptors, which are 
approximately one order of magnitude weaker in rat brain. 
In agreement with its higher affinity for 5-HT
3
 receptors and 
SERT, ex vivo autoradiography experiments show that vor-
tioxetine occupies these sites at lower doses (0.3–10 mg/kg), 
whereas higher doses are required to occupy 5-HT
1B
, 5-HT
1A
, 
and 5-HT
7
 receptors.
In vivo microdialysis studies showed that vortioxetine 
increases the extracellular concentration of serotonin (5-HT) 
more than the serotonin selective reuptake inhibitors (SSRI) 
in depression-related areas, such as the medial prefrontal 
cortex (mPFC) and the hippocampus.8,10 Vortioxetine also 
increases the extracellular concentration of noradrenaline 
(NA), dopamine (DA), acetylcholine (Ach), and histamine 
(HA) in rat brain.8,10 The greater elevations of extracellular 
5-HT evoked by vortioxetine likely result from its multimodal 
mechanism of action. Indeed, various 5-HT receptors for 
which vortioxetine shows high affinity have been implicated 
in the mechanism of action of antidepressant drugs,11 and 
several of them participate in negative feedback mechanisms 
that limit the action of SSRI.12,13 In particular, the blockade 
of 5-HT
3
 receptors by vortioxetine may be involved in these 
neurochemical effects, since the 5-HT
3
 receptor antagonist 
ondansetron augments the increase in extracellular 5-HT 
produced by SSRI in mPFC and the hippocampus.8 Likewise, 
vortioxetine (but not escitalopram) increased the discharge 
rate of pyramidal neurons in rat mPFC, an effect that depends 
on 5-HT
3
 receptor blockade.14 
Vortioxetine’s actions at 5-HT receptors may be involved 
in the elevations of extracellular DA, NA, Ach, and HA 
evoked by the drug in rat brains,8 given the multiple and 
mutual interactions between these neurotransmitter systems. 
Likewise, this mechanism may also explain the greater 
elevations in extracellular 5-HT produced by vortioxetine in 
comparison with the SSRI at a given occupancy of SERT.9
Vortioxetine shows good bioavailability after oral dos-
ing (75%) with a t
max
 of 7–8 hours and a half-life (t
1/2
) of 
57 hours, and achievement of stable plasma concentrations 
in 2 weeks. The rate of binding to plasma proteins was 96%. 
It is metabolized by several hepatic P-450 isoenzymes such 
as CYP2D6, CYP3A4/5, CYP2C9, CYP2C19, CYP2A6, 
CYP2C8, and CYP2B6.15 It does not inhibit nor activate 
any of them, showing linear kinetics. Its main metabolite 
is inactive.
Efficacy of vortioxetine
Twelve clinical trials have been carried out to assess the 
short-term efficacy (6 or 8 weeks) of vortioxetine (see 
Table 1).16–27 Two long-term trials have been conducted to 
assess its efficacy in preventing relapses.
Of the 12 efficacy trials for new episodes of depression, 
eight were positive for vortioxetine versus placebo,19–21,23–27 
while three studies (two of which were carried out only 
in the US) showed no significant differences versus 
placebo,16,18,22 with one failed study.17 In one of the negative 
trials, Jain et al16 includes a detailed discussion of most of 
the factors that can affect placebo response. 
Six of the positive studies achieved positive results in 
the treatment arms that received 5–20 mg/day. In contrast, 
in two other positive studies, vortioxetine was superior to 
placebo only in the highest dose arms (20 mg/day) but not 
at 10 or 15 mg/day. One of the trials17 was considered to be 
“failed” because neither vortioxetine nor the active compara-
tor (duloxetine) were superior to placebo. Another trial18 was 
clearly negative for vortioxetine because the results were 
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positive for the active comparator (duloxetine). However, it 
is important to note that one of the inclusion criteria required 
that subjects not be resistant to duloxetine, and this require-
ment could have biased the results. In the other two nega-
tive trials, vortioxetine was compared only to placebo and 
the lack of an active comparator makes the results of those 
trials more uncertain. 
Patients who respond to vortioxetine typically do so after 
approximately 2 weeks of treatment, with the maximum 
response seen near the fourth week. However, McIntyre 
et al19 observed significant differences versus placebo in the 
first week at doses of 20 mg/day, whereas these differences did 
not emerge until the second week in the 10 mg/day arm.
Table 1 shows the efficacy data and other relevant details 
of these 12 trials. Six of these 12 studies have been published 
as articles in various medical journals while the remaining 
six studies have not yet been published, but were presented 
as posters in relevant congresses. All these trials involve 
patients who presented an episode of major depression (Diag­
nostic and Statistical Manual of Mental Disorders [DSM-IV] 
criteria) of at least 3 months’ duration without any history 
of treatment resistance. The only exception was the direct 
comparison trial of vortioxetine and agomelatine, conducted 
in patients who showed no or inadequate response to SSRI/
serotonin–norepinephrine reuptake inhibitors (SNRI) for at 
least 6 weeks at maximal doses.20 
These 12 studies were conducted in patient populations 
ranging 18–75 years, with a mean age of 42–48 years. 
Females made up the majority of patients (62.5%–78%) in 
all the samples. Five of the studies were performed only in 
the US,16,18,21–23 while the remaining seven were conducted 
in numerous other countries.17,19,20,24–27
The main variable assessed in all the studies was the 
change in the Montgomery–Åsberg Depression Rating 
Scale (MADRS) or in the Hamilton Depression Rating Scale 
(HAMD). Baseline scores on the MADRS ranged from 29 to 
34 depending on the inclusion criteria of the particular study, 
which varied slightly. The percentage of patients in each trial 
who completed the full study ranged from 74%–90%. Two 
trials involved only ambulatory patients while another two 
included both ambulatory and inpatients (without differen-
tial analysis); in the remaining studies, no details regarding 
this aspect have been provided. There were no significant 
differences between treatment groups in any of the trials in 
terms of demographic or clinical variables that could have 
biased the results.
All the trials were performed on an intention-to-treat 
basis with the last observation carried forward (LOCF) 
but according to the full analysis set (FAS) version, which 
includes all patients who have been assessed at least once 
after randomization.
Two medium/long-term efficacy studies of vortioxetine 
have been performed. One of these was a randomized double-
blind controlled clinical trial designed to assess the ability 
of vortioxetine to prevent new relapses of depression.28 
No less interesting is the open-label efficacy extension study 
carried out by Baldwin et al29 under conditions considered 
closer to “real life”. Although this was a tolerability study, 
the complementary efficacy data are relevant.
The first of these long-term trials28 was conducted in a 
sample of 639 patients recruited in 17 countries. The design 
consisted of a 12-week period during which patients were 
treated on an open-label basis with flexible doses of vortiox-
etine (5–10 mg/day); after the eighth week, the dose was fixed 
for the remainder of the study period. Patients in remission 
(MADRS 10) were randomized to receive double-blind 
treatment with placebo or with the same dose level of vortiox-
etine that was needed to achieve remission. Final assessment 
was performed when the last patient recruited had finalized 
the required 24 weeks of follow-up (the first patients included 
in the trial were followed for 64 weeks). A significant differ-
ence was found in the mean relapse rate between patients in 
the placebo group and patients who continued with the active 
drug (26% versus [vs] 13%, P=0.0035), thus confirming the 
ability of vortioxetine to retain its therapeutic activity.
In the second long-term trial,29 all patients received 
5 mg/day during the first week; after this time, the open-
label design permitted the researchers to administer flexible 
doses (between 2.5 and 10 mg/day) at their discretion. This 
approach approximates the real conditions of antidepressant 
treatment, except that the range of doses was perhaps smaller 
than it would have been in real conditions. The treatment 
period was 12 months. Although the main outcomes of that 
study are related to tolerability, the treatment “effectiveness” 
outcomes are also of interest: the MADRS decreased by a 
mean of 8 points, the percentage of responders increased from 
63% to 94%, and remissions (MADRS 10) rose from 42% 
to 83%. Moreover, among the patients in remission at the 
start of the study, the relapse rate was only 9.7%.
Few clinical trials have been performed to assess effi-
cacy in switching from one antidepressant to another in 
resistant depression. For this reason, the trial carried out by 
Häggström et al20 is particularly noteworthy. Their study was 
conducted in patients who did not respond (or responded 
inadequately) to SSRI or SNRI monotherapy drugs (citalo-
pram, escitalopram, paroxetine, sertraline, duloxetine, and 
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venlafaxine) administered at appropriate doses (up to the 
maximum dose allowed) and for sufficient periods of time 
(at least 6 weeks). All patients in the study were considered 
candidates for a monotherapeutic drug–switching strategy. 
Given the resistant nature of these patients’ depression, this 
trial could be considered a “paradigm shift” in the pharma-
cological treatment of depression, as the patients were ran-
domized to receive either: a) agomelatine, a melatoninergic 
agonist that induces an increase in the release of NA and 
DA30 or b) vortioxetine, which, in addition to antagoniz-
ing SERT, possesses the multimodal capacities described 
previously, which promote the release of catecholamines 
in some regions of the brain.10 The prescribed doses of both 
drugs assured maximum therapeutic activity: 25–50 mg/day 
of agomelatine versus 10–20 mg/day of vortioxetine. After 
12 weeks, patients in both groups had improved significantly, 
with a mean decrease of 16.5 points on the MADRS for 
the vortioxetine group versus 14.4 points for agomelatine 
(P0.01). Vortioxetine was shown to be significantly bet-
ter in therapeutic response (50% improvement in MADRS; 
P0.01) and in remissions (MADRS 10; P0.001). 
Despite the theoretical limitation of this study (ie, lack of a 
placebo arm), this was a non-experimental patient population 
recruited from daily clinical practice after having received 
conventional treatment. As a result, this population was 
much closer to “real world” patients.
Vortioxetine tolerability
The safety data from the 12 short-term efficacy studies are 
shown in Table 2. In general, tolerability was excellent. 
The most common adverse events (AEs), with an incidence 
rate 5%, were nausea, vomiting, constipation, and head-
aches. In some trials, vortioxetine resulted in an incidence 
rate for these AEs that was similar to that for placebo and 
better than the active comparators. However, the incidence 
of AEs for vortioxetine was higher than for placebo only at 
the highest (20 mg/day) dose arms: Boulenger et al27 66.2% 
versus 50.6%; Jacobsen et al21 68.7% versus 62.4%; and 
Mahableshwarkar et al23 81.2% versus 70.4%. 
In most of the studies, at doses of 10 mg or more, 
AE-related withdrawals were greater in the vortioxetine 
arms versus placebo and lower than the active comparator, 
except in the Mahableshwarkar et al study.23 However, at 
doses 10 mg, vortioxetine showed no differences versus 
placebo in terms of withdrawals. Detailed data on withdraw-
als due to AEs are shown in Table 3.
No relevant differences between vortioxetine and pla-
cebo have been observed in terms of vital signs,  including U
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arterial blood pressure and heart rate. Similarly, no 
alterations in any cardiac parameters – including the QT 
segments – have been seen on electrocardiographic exami-
nations, with no significant differences between placebo 
and vortioxetine.
One particularly interesting characteristic of vortioxetine 
is that it appears to have no effect on weight, in contrast 
to other antidepressants in which the association between 
induction of weight gain and the presence of other metabolic 
alterations has been established. This is important given 
that weight gain and sexual dysfunction are the main AEs 
responsible for poor therapeutic adherence. 
Sexual dysfunction
Deterioration in sexual function is the AE that most concerns 
both patients and clinicians alike. A recent meta-analysis on 
this topic31 assessed the incidence of emerging sexual dys-
function reported in studies of antidepressant medications. 
That meta-analysis found that only antidepressant drugs 
without serotoninergic activity were able to maintain low 
rates of sexual dysfunction similar to placebo. However, to 
achieve remission, most patients require an antidepressant 
with serotoninergic activity, which is why SSRI/SNRI are 
used in most monotherapy treatments. In contrast, cate-
cholaminergic drugs are used mainly in combined therapies, 
as occurs with bupropion or mirtazapine. 
The proportion of patients who develop treatment-related 
emerging sexual dysfunction will depend on the specific 
medication. A few notable examples include sertraline (80% 
of patients), venlafaxine (79.8%), duloxetine (41%), and 
escitalopram (37%).31
Clinical trials of vortioxetine performed in acute patients 
indicate that the percentage of patients who develop emerging 
sexual dysfunction is considerably lower for this drug than for 
other antidepressants, even though vortioxetine is essentially 
a serotoninergic agonist. In the studies that have reported 
spontaneous sexual dysfunction, the proportion of patients 
with sexual dysfunction was the same or close to placebo 
and significantly lower than that for the active comparators 
venlafaxine24 and duloxetine.17,26 However, it should be noted 
that when a specific instrument, such as the Arizona Sexual 
Experience Scale (ASEX) was used, the percentage of sexual 
dysfunction increased in all groups treated with 20 mg/day 
of vortioxetine. However, this increase was only significant 
versus placebo in one study.21
The data from the two long-term studies of vortioxetine 
merit special attention, especially considering the relevance 
of sexual dysfunction in the general population: premature 
ejaculation and erectile dysfunction in 14% and 10% of U
S
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men, respectively, and hypoactive sexual desire disorder in 
16%–46% of premenopausal women.32 
In the randomized, double-blind, long-term efficacy 
study,28 sexual dysfunction was observed in two subjects 
in the placebo group (erectile dysfunction and anorgasmia, 
respectively) and three in the vortioxetine (5–10 mg/day) 
group (erectile dysfunction, libido reduction, and anorgasmia, 
respectively) during the controlled phase of the study. Addi-
tionally, it is worth pointing out that four patients became 
pregnant during this treatment period and of those patients, 
three elected to interrupt the pregnancy while one gave birth 
to a healthy boy.
In the open-label extension study,29 six patients (out of a 
total of 336) – four men and two women – developed emerg-
ing sexual dysfunction. Four of these patients experienced 
reduced sexual impulse: two experienced a total loss of sexual 
drive while the remaining two developed, respectively, erectile 
dysfunction and anorgasmia. These cases of sexual dysfunction 
are understood to be “emergent”, that is, arising after treatment 
initiation, without regard to prior sexual satisfaction status.
Available data on the pharmacological mechanism 
of action that could explain the scant induction of sexual 
 dysfunction by vortioxetine compared to other antidepres-
sants are scarce. Vortioxetine, in contrast to SSRI/SNRI, has 
an affinity for various serotoninergic receptors as discussed 
earlier. However, we do not know what role if any these 
receptors have in modulating sexual impulse. However, 
one study that could shed light on this question is the one 
carried out by Amstislavskaya and Popova,33 who showed 
that plasma testosterone levels in male rats treated with SSRI 
and in proximity to a female recovered when the rats were 
treated with a potent antagonist of the 5-HT
3
 receptor, such 
as ondansetron. Although this is only a scientific specula-
tion, the role of this receptor and of other receptors for which 
vortioxetine has an affinity could present an interesting line 
of research for further investigation into the relationship 
between increased serotoninergic activity and decreased 
sexual impulse.
Cognitive function
Since tricyclic antidepressants were excluded as first-line 
treatments for depression, the devastating effects on cogni-
tive function that these drugs can cause in older or elderly 
adult patients have practically disappeared from daily 
Table 3 withdrawal due to Aes in vOR double-blind, randomized trials in patients with major depressive disorder
Country and authors Placebo 1–2.5 mg/day  
of VOR
5 mg/day  
of VOR
10–15 mg/day  
of VOR
20 mg/day  
of VOR
60 mg/day  
of DLX
225 mg/day  
of VLFX
25–50 mg/day 
of AGO
11 countries
Alvarez et al24
3.8 2.7 7 14.2
20 countries
Baldwin et al17
8 6 11 9 12
US
Mahableshwarkar et al18
4.57 4.57 7.84 11.18
US
Jain et al16
(Primary care, psychiatrist,  
private practice, academic  
centers, etc)
3.66 3
14 countries
Henigsberg et al25
1.42 2.14 0.71 3.57
7 countries
Katona et al26
4.13 6.41 9.93
13 countries
Boulenger et al27
3.75 6.71 11.2 4.79
14 countries (EUR)
Häggström et al20
5.9 9.5
US
Jacobsen et al21
1.27 5.81 4.66
US
Mahableshwarkar et al22
3.75 5.09/7.89
US
Mahableshwarkar et al23
2.48 9.52 9 6.57
12 countries
Mcintyre et al19
4.1 3.6 5.3
Abbreviations: Aes, adverse effects; AGO, agomelatine; DLX, duloxetine; eUR, europe; vLFX, venlafaxine; vOR, vortioxetine.
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clinical practice. However, it is not unusual for patients 
treated with SSRI/SNRI to complain about impaired cogni-
tive performance (especially older people), which is probably 
due to excessive neuromodulation of the release of cate-
cholamines, which occurs with increased 5-HT function. 
The excellent study by Katona et al26 on the efficacy of 
vortioxetine (with duloxetine as the active comparator) in the 
treatment of depression in the elderly population appropri-
ately included an assessment of cognitive function. The fact 
that age is a determining factor in “natural cognitive decline” 
as well as in drug-induced cognitive dysfunction implies 
that it is reasonable to extrapolate the results to younger 
populations. In their study, the inclusion criteria excluded 
patients with a mini–mental state examination (MMSE) score 
of 24 points, thus eliminating all cases with neurodegenera-
tive disease. To evaluate the effects of treatment on cognitive 
function, subjects underwent an examination at baseline 
and then at the end of the study. Verbal learning, memory, 
and processing speed were all assessed using the following 
tests (administered in this order): the Rey Auditory Verbal 
Learning Test (RAVLT) and the digit symbol substitution 
test (DSST).
Patients randomized to the active drug showed sig-
nificantly greater improvement versus placebo and versus 
duloxetine. The effect size compared to placebo was assessed 
via path analysis, with the results showing that vortioxetine 
had an 83% direct effect on the DSST score versus 26% 
for duloxetine. Similarly, in the RAVLT, vortioxetine had 
an effect size of 71% versus 65% and in re-memorization, 
72% versus 66%.
These data suggest that vortioxetine does not induce 
cognitive problems but may actually improve the baseline 
condition. This makes this drug especially recommendable in 
older patients and in patients who complain of cognitive 
impairment during treatment. 
Discussion
The proportion of negative clinical trials for a new drug varies 
greatly. In some instances, up to 50% of trials were negative 
in antidepressants that ultimately achieved final regulatory 
approval.34 In the case of vortioxetine, with the exception of 
the “failed” study by Baldwin et al17 only three trials failed 
to show significant differences between the active drug and 
placebo. In one of those trials,16 the authors discuss in detail 
the possible reasons that might explain the negative results 
of a clinical trial and they analyze their own results in this 
context. Among the most important reasons they give is 
that researchers might inadvertently “inflate” the baseline 
severity of patients included in the study as a consequence 
of the inclusion criteria, with subsequent overestimation of 
the therapeutic response.35 In the same study, a “post-hoc” 
analysis showed that this exaggeration of baseline severity 
likely occurred in the recruitment centers with the fastest 
enrollment or in those with fewer screen failures. The 
expectations of subjects who have previously participated 
in other similar clinical trials could also have an effect on 
therapeutic response.36
The three negative vortioxetine studies were carried out 
entirely in the US (see Table 1). The well-known profes-
sionalization of the evaluators and patients in clinical trials 
that are conducted in the US supports the arguments given 
above with regards to inflation of the response to placebo. 
This is an issue that the regulatory agencies (US Food and 
Drug Administration and European Medicines Agency) need 
to address as soon as possible. An impeccable study design 
with follow-up according to “Good Practices” is not enough. 
The factors and motivations surrounding sample selection 
are important aspects that must be considered.
Notwithstanding those three negative studies, it is impor-
tant to note that vortioxetine has been proven superior to 
placebo and/or active comparators in eight other studies (see 
Table 1). However, for reasons that have already been dis-
cussed in the present review, even though some of the studies 
found significant differences versus placebo, these differ-
ences do not necessarily imply a large difference between 
the active drug and placebo. The efficacy/registration 
studies of a new drug may not show an important size 
effect. To gain a better understanding of these differences, 
we recommend that readers consult the excellent systematic 
review of vortioxetine carried out by Citrome, in which these 
differences are discussed in depth.37
Vortioxetine is undoubtedly a good first-line therapeutic 
option in patients with depression. Vortioxetine also presents 
some remarkable differences when compared to the drugs 
currently on the market, and these characteristics indicate 
that it could also be used as a second-line therapy when the 
results of first-line treatments are unsatisfactory. Clinicians 
may wish to consider switching from the treatment in course 
to vortioxetine when one of the three conditions following 
arise, even if the current treatment is considered successful 
in terms of therapeutic response.
First, in cases in which the patient complains about 
cognitive function after the depression has improved: the 
decrease in catecholamine release triggered by the increase of 
serotoninergic activity during treatment with SSRI explains 
why attention and cognitive performance are lower than 
expected. The two studies that assessed the influence of vor-
tioxetine on cognitive function have shown that it preserves 
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 cognitive function in elderly patients26 and even improves it 
in nonresponders. McIntyre et al very recently reported, at the 
American College of Neuropsychopharmacology (ACNP), 
the results of a clinical trial that supports the positive effect of 
vortioxetine on cognitive function in addition to its efficacy 
versus placebo.19 In their study (no active comparator), the 
authors showed improved cognition even in patients who did 
not meet the criteria for therapeutic response.
Secondly, in patients who experience a treatment-related 
decline in sexual functioning, vortioxetine may offer an 
alternative. Deterioration in preexisting sexual function is 
the AE that causes the greatest concern among both patients 
and clinicians. In patients who show an adequate therapeutic 
response to SSRI/SNRI but in whom treatment compliance is 
compromised by the presence of emerging sexual dysfunc-
tion, the switch to vortioxetine can improve the situation. In 
this regard, it is important to keep in mind that only the 20 mg/
day dose of vortioxetine is associated with greater sexual 
dysfunction than placebo. The frequency of emerging sexual 
dysfunction has been widely discussed by other authors.31
Finally, in patients with an inadequate therapeutic 
response – even at maximum dosage – switching to vor-
tioxetine may improve the response. The scant information 
available about the value of switching to another antidepres-
sant gives special relevance to the clinical trial that directly 
compared vortioxetine to agomelatine.20 Maintaining a 
patient in monotherapy is a good alternative to the usual 
strategy of combined treatments with other antidepressants 
or to the addition of lithium – common strategies in cases 
with poor therapeutic response – but these strategies can 
increase the number of AEs. It is particularly relevant that the 
sample selection in that trial was much closer to “real world” 
patients than in the other studies of vortioxetine, which thus 
compensates for the lack of a placebo arm.
The multimodal mechanism of action of vortioxetine may 
be involved in the procognitive activity and low incidence 
of sexual side effects observed in Phase II/III clinical trials. 
Further studies are required to confirm these observations 
and to examine the exact mechanisms involved. Overall, 
the pharmacological properties of vortioxetine differ from 
those of existing antidepressant drugs. However, only its 
extensive use in large patient populations will allow us to 
assess whether the distinct preclinical properties of vortiox-
etine translate into a clinical profile that differs from that of 
SSRI and SNRI. 
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